Equities Analysts Offer Predictions for ACAD FY2025 Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of ACADIA Pharmaceuticals in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan anticipates that the biopharmaceutical company will post earnings per share of $0.24 for the year. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.70 per share.

Several other brokerages also recently commented on ACAD. Needham & Company LLC reissued a "buy" rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a report on Thursday, November 7th. Guggenheim lowered shares of ACADIA Pharmaceuticals from a "buy" rating to a "neutral" rating and cut their price target for the stock from $23.00 to $20.00 in a report on Friday, January 3rd. Raymond James reaffirmed a "market perform" rating on shares of ACADIA Pharmaceuticals in a research report on Thursday, October 10th. StockNews.com lowered shares of ACADIA Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Thursday, November 14th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $27.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. Seven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $25.25.

ACADIA Pharmaceuticals Trading Down 2.1 %

Shares of NASDAQ ACAD traded down $0.41 during midday trading on Thursday, hitting $18.67. The company's stock had a trading volume of 1,724,259 shares, compared to its average volume of 4,492,327. ACADIA Pharmaceuticals has a one year low of $14.15 and a one year high of $27.94. The stock has a fifty day moving average price of $17.26 and a 200 day moving average price of $16.59. The firm has a market capitalization of $3.11 billion, a price-to-earnings ratio of 23.94 and a beta of 0.37.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $0.20 EPS for the quarter, topping analysts' consensus estimates of $0.14 by $0.06. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%. The business had revenue of $250.40 million for the quarter, compared to analyst estimates of $248.83 million. During the same period last year, the company posted ($0.40) earnings per share. ACADIA Pharmaceuticals's quarterly revenue was up 18.3% compared to the same quarter last year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC lifted its stake in shares of ACADIA Pharmaceuticals by 380.3% in the 4th quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company's stock valued at $45,576,000 after purchasing an additional 1,966,607 shares during the last quarter. Barclays PLC lifted its position in ACADIA Pharmaceuticals by 126.2% in the third quarter. Barclays PLC now owns 277,565 shares of the biopharmaceutical company's stock worth $4,269,000 after buying an additional 154,854 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in ACADIA Pharmaceuticals during the third quarter worth $483,000. Burney Co. bought a new position in ACADIA Pharmaceuticals during the fourth quarter valued at $6,953,000. Finally, Fred Alger Management LLC raised its stake in shares of ACADIA Pharmaceuticals by 19.8% in the second quarter. Fred Alger Management LLC now owns 2,704,439 shares of the biopharmaceutical company's stock valued at $43,947,000 after acquiring an additional 446,875 shares during the period. Institutional investors own 96.71% of the company's stock.

Insider Activity

In other ACADIA Pharmaceuticals news, CFO Mark C. Schneyer sold 10,259 shares of the firm's stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total transaction of $172,453.79. Following the completion of the transaction, the chief financial officer now owns 53,302 shares in the company, valued at $896,006.62. This trade represents a 16.14 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, COO Brendan Teehan sold 10,329 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $16.81, for a total value of $173,630.49. Following the transaction, the chief operating officer now owns 62,105 shares of the company's stock, valued at $1,043,985.05. This represents a 14.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 24,661 shares of company stock worth $414,551 over the last ninety days. Corporate insiders own 28.30% of the company's stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.